Senere undersøgelser indikerer, at det er muligt at administrere gemcitabin i lavere doser med samtidig strålebehandling med en forudsigelig toksicitet, som i et fase II studie af ikke- småcellet lungecancer, hvor der blev anvendt torakalbestråling i doser på 66Gy samtidig med gemcitabin (600 mg/ m2 4 gange) og cisplatin (80 mg/ m2, to gange) i løbet af 6 uger.
Studies done subsequently have suggested that it is feasible to administer gemcitabine at lower doses with concurrent radiotherapy with predictable toxicity, such as a phase II study in non-small cell lung cancer, where thoracic radiation doses of 66 Gy were applied concomitantly with an administration with gemcitabine (600 mg/m2, four times) and cisplatin (80 mg/m2 twice) during 6 weeks.